R&D
- Aesthetics
Localized Fat Reduction, Cellulite,
Hyperpigmentation, Skin Aging
- Therapeutics
Dercum's Disease, Lipoma, Osteoarthritis, Central Obesity, Fatty Liver
-
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market -
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market -
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market -
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
Discovery
Preclinical
Phase I
Phase II
Phase III
NDA/
Market
-
CBL-514
-
CBA-539
-
CBO-012
-
CBF-520
-
CBL-539, a long-acting injectable product, is designed for a more efficacious and safe treatment for refractory melasma by inhibiting melanin production. Besides, CBL-539 was evidenced that could recover skin elasticity by increasing collagen production.
Conditions/Indications： Hyperpigmentation, Skin aging
About Caliway
In Caliway, we are driven to breakthrough drug discovery of novel small-molecule therapeutics for medical aesthetics and inflammatory disease. By developing innovative drugs, we aim to provide new treatment options for the indications in which clinical needs remain unmet.
-
ADVANTAGE
Well-Experimented Team of Experts
Caliway's research team comprises experts with deep knowledge and experience in drug discovery, business development, and regulatory affairs. We develop innovative new strategies with high safety to address medical conditions with no effective treatments available. -
ADVANTAGE
Target Emerging Markets
In Caliway, the diseases we are targeted on affect millions of people, often in their most productive years. We are on a mission to combine science, medicine, and advocacy with improving people's lives suffering from illnesses or life-threatening diseases. -
ADVANTAGE
Global IP Protection
We have exclusive rights to benefit from the commercial use of our products, such as producing, selling, and exporting worldwide.
-
10
2023
Caliway's CBL-514 Achieved Better Efficacy than Liposuction, Reducing over 300mL of Subcutaneous Fat on Average in CBL-0202 Study
CBL-0202 Phase 2 study results met all the primary and secondary endpoints.
-
09
2023
Caliway Announces the Completion of Subject Recruitment in the CBL-0201EFP Phase 2-stage 2 Study Evaluating the CBL-514 in Cellulite Treatment
Caliway announced the completion of subject recruitment in the CBL-0201EFP Phase 2-stage 2 study.
-
09
2023
The Positive Topline Results from the CBL-514 Phase 2 Study for Dercum’s Disease Showed 64.5% of Painful Lipomas with Complete Clearance or Dimensions Reduction of more than 50% and Significantly Reduced Pain by 4.7 Points
CBL-0201DD Phase 2 study met the primary and all secondary endpoints.
-
07
2023
Caliway Receives IND approval from the U.S. FDA for the CBL-0205 Phase 2b Study Evaluating CBL-514 in Abdominal Subcutaneous Fat Reduction
Caliway announces that the U.S. FDA has approved the company’s IND application for CBL-514 injection’s CBL-0205 Phase 2b Study.
-
